Company intelligence / Profile preview

Insero Health

Miami, Florida, United Statesinseroadvisors.com ↗

Ownership: Private
Development stage: Other

Overview

Insero Health is developing novel therapies derived from natural products, with a focus on epilepsy. Its lead compound is huperzine, licensed from Harvard University for use in epilepsy and other indications. Huperzine has shown promise in preclinical models for epilepsy. The company also holds an exclusive license from Yale University for a synthetic manufacturing process enabling scalable production of huperzine. As of the last update, the company aimed to move its lead candidate into Phase 1/2 clinical trials.

Therapeutic areas: Neurology
Modalities: Small moleculeNatural product derivative
Industry: Biotech

Partnerships

Harvard University (exclusive license on patents related to huperzine)Yale University (exclusive license on synthetic manufacturing process for huperzine)

Beyond the preview

Go deeper on Insero Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Insero Health.

Explore the full profile